Lilly's Basaglar Insulin Glargine Will Be US Blockbuster

With second-quarter sales of over $232m in the US, Eli Lilly's Basaglar hybrid insulin glargine is close to becoming a $1bn blockbuster on a proforma annual basis. Global sales of the brand are already tracking well ahead of $1bn.